Coya Therapeutics, Common Stock Alpha and Beta Analysis
| COYA Stock | 6.65 0.27 4.23% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Coya Therapeutics, Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Coya Therapeutics, over a specified time horizon. Remember, high Coya Therapeutics,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Coya Therapeutics,'s market risk premium analysis include:
Beta 1.73 | Alpha 0.17 | Risk 5.98 | Sharpe Ratio 0.0533 | Expected Return 0.32 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Coya |
Coya Therapeutics, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Coya Therapeutics, market risk premium is the additional return an investor will receive from holding Coya Therapeutics, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Coya Therapeutics,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Coya Therapeutics,'s performance over market.| α | 0.17 | β | 1.73 |
Coya Therapeutics, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Coya Therapeutics,'s Buy-and-hold return. Our buy-and-hold chart shows how Coya Therapeutics, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Coya Therapeutics, Market Price Analysis
Market price analysis indicators help investors to evaluate how Coya Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Coya Therapeutics, shares will generate the highest return on investment. By understating and applying Coya Therapeutics, stock market price indicators, traders can identify Coya Therapeutics, position entry and exit signals to maximize returns.
Coya Therapeutics, Return and Market Media
The median price of Coya Therapeutics, for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 6.66 with a coefficient of variation of 15.12. The daily time series for the period is distributed with a sample standard deviation of 1.04, arithmetic mean of 6.88, and mean deviation of 0.77. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 115000 shares by Arun Swaminathan of Coya Therapeutics, at 4.05 subject to Rule 16b-3 | 09/10/2024 |
2 | Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of P... | 09/16/2024 |
3 | Coya Therapeutics Announces Closing of 10.0 Million Private Placement | 10/23/2024 |
4 | Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Mo... | 10/28/2024 |
5 | Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 in Alzheimers Disease Presented at the Clinical Tria... | 10/29/2024 |
6 | Acquisition by Arun Swaminathan of 5000 shares of Coya Therapeutics, at 7.3378 subject to Rule 16b-3 | 11/11/2024 |
7 | Fred Grossman Purchases 2,710 Shares of Coya Therapeutics, Inc. Stock | 11/13/2024 |
8 | Coya therapeutics CFO David Snyder buys 12,934 in stock | 11/14/2024 |
9 | Coya Therapeutics, Inc. Short Interest Update | 11/19/2024 |
10 | Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference | 11/25/2024 |
About Coya Therapeutics, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Coya or other stocks. Alpha measures the amount that position in Coya Therapeutics, Common has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Graham Number | 7.87 | 8.27 | Receivables Turnover | 0.72 | 0.64 |
Coya Therapeutics, Upcoming Company Events
As portrayed in its financial statements, the presentation of Coya Therapeutics,'s financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Coya Therapeutics,'s leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Coya Therapeutics,'s public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Coya Therapeutics,. Please utilize our Beneish M Score to check the likelihood of Coya Therapeutics,'s management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Coya Therapeutics,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Coya Therapeutics, Backtesting, Coya Therapeutics, Valuation, Coya Therapeutics, Correlation, Coya Therapeutics, Hype Analysis, Coya Therapeutics, Volatility, Coya Therapeutics, History and analyze Coya Therapeutics, Performance. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Coya Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.